Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00887588 · ClinicalTrials.gov registry record · Phase 2
LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 307
- Enrollment target
NCT00887588 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 307 participants.
The verdict
NCT00887588, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 307 participants
- Enrollment target
Study Summary
The study will assess the effects of 36 weeks of treatment with LCZ696 compared to valsartan on N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) in patients with chronic heart failure and preserved left-ventricular ejection fraction.
Interventions
- DRUG Placebo
- DRUG Valsartan
- DRUG LCZ696
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 307 participants |
| Start Date | 2009-11 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00887588
The ClinicalTrials.gov registry entry for NCT00887588 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 307 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00887588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00887588 about?
NCT00887588 is a clinical study titled "LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction". The study will assess the effects of 36 weeks of treatment with LCZ696 compared to valsartan on N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) in patients with chronic heart failure and preserved left-ventricular ejection fraction.
What is the current status of trial NCT00887588?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 307 participants. The study started on 2009-11. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00887588?
The interventions under investigation include: Placebo (DRUG), Valsartan (DRUG), LCZ696 (DRUG).
Who is sponsoring clinical trial NCT00887588?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.